Aligos Therapeutics, Inc. ALGS 深 滬
已收盤 05-08 16:00:00 美东时间
6.44
+0.410
+6.80%
華盛通- 最 高6.57
- 今 開6.11
- 成交量 31.79万股
- 最 低 5.86
- 昨 收 6.03
- 總市值 3470.02万
- 52周最高 13.6892
- 市盈率 靜 --
- 換手率 5.90%
- 52周最低 5.12
- 委 比 -20.32%
- 總股本 538.82万
- 歷史最高 937.75
- 量 比 2.43
- 振 幅 11.77%
- 歷史最低 3.76
- 每 手 1
- 風險率 1.62%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Why Akamai Shares Are Trading Higher By 26%; Here Are 20 Stocks Moving Premarket
Akamai Technologies Inc (NASDAQ: AKAM) rose in pre-market trading after reporting strong Q1 results and raising FY26 sales guidance.
05-08 17:54
Market-Moving News for April 16th
MYSE: 280% | Myseum shares are trading higher. The company announced a rebrand to Myseum.AI. ALGS: 48% | Aligos Therapeutics shares are trading higher after the company announced that it has entered into
04-16 19:26
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers BNB Plus (NASDAQ:BNBX) stock moved upwards by 12.7% to $0.65 during Tu...
04-15 05:05
Aligos Therapeutics Announces First Interim Analysis Results From Phase 2 B-SUPREME Study; FDA Grants Fast Track Designation
Received FDA Fast Track Designation for pevifoscorvir sodium for the treatment of chronic hepatitis B virus infectionHBeAg- cohort sample size increased to optimize powering; futility criteria not metStudy drugs were
04-15 04:07
美股大行评级 | 大摩、高盛上调Denali Therapeutics目标价；Chewy、沛齐遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Atossa Therapeutics"买入"评级，目标价从7美元升至25美元；Needham：维持Nkarta"买入"评级，目标价从10美元升至11美元
03-27 10:22
美股大行评级 | 最高700美元！大摩、瑞银等10家大行集体上调美光目标价；通用磨坊、梅西百货、SailPoint等遭多家大行下调目标价
今日重点评级关注：RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从32美元升至35美元；巴克莱：维持CytomX医疗"超配"评级，目标价从10美元升至16美元
03-20 15:53
Jefferies Assumes Aligos Therapeutics at Buy, Lowers Price Target of $48
Jefferies analyst Anthea Li assumes Aligos Therapeutics (NASDAQ:ALGS) with a Buy rating and lowers Price Target of $48.
03-20 03:40
美股大行评级 | 甲骨文绩后分歧大！小摩上调评级至"超配"，目标价缺降至210美元；科尔士百货、AVAV、Blend Labs、Domo遭多家大行下调评级
今日重点评级关注：LUCID CAPITAL MARKETS：上调INmune Bio评级至"买入" 目标价从2美元升至9美元；Clear Street：维持MoonLake Immunotherapeutics Class A"买入"评级，目标价从45美元升至70美元
03-12 12:34
HC Wainwright & Co. Reiterates Buy on Aligos Therapeutics, Maintains $50 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Aligos Therapeutics (NASDAQ:ALGS) with a Buy and maintains $50 price target.
03-12 01:19
Aligos Therapeutics Earnings Report: Q4 Overview
The Q4 earnings report for Aligos Therapeutics (NASDAQ:ALGS) was released on Th...
03-05 21:14
